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Immuno-Oncology Medicines: Policy Implications and Economic Considerations 




Significant progress has taken place in the field of cancer immunotherapy in recent years. Cancer immunotherapy, particularly immune 
checkpoint inhibitors, have shown rather dramatic results and are believed to have completely transformed the field of oncology. 
However, these transformational therapies are more expensive than previous cancer therapies. As more cancer immunotherapy agents 
are being developed, with some already being marketed, it is important to consider how economic constraints will shape health policy 
and value assessment related to these agents. A number of strategies have been suggested to alleviate the price burden and the 
ensuing concerns about the sustainability of publicly funded healthcare systems. Among these strategies, value-based pricing (VBP) for 
innovative drugs dominates the headlines in the field of oncology. The specifics of how VBP may be implemented in the United States is 
still unclear. Nonetheless, policy reform and economic considerations will have to be incorporated into the planning of VBP. The 
objective of this paper is multifold: (i) to identify the factors affecting the impact of cancer immunotherapy on healthcare cost; (ii) to 
critically appraise current approaches used to assess the value of novel cancer therapies; (iii) to assess the methodological challenges 
associated with the economic evaluation of cancer immunotherapy. As the health care system in the U.S transitions toward a value-
based model, the need for a formal value assessment framework is warranted in cancer immunotherapy. 




Cancer causes significant morbidity and mortality in the 
United States (U.S.) and imposes a substantial economic 
burden on individuals and society as a whole.1-3 Despite 
therapeutic advances in chemotherapy and targeted therapy, 
the prognosis of most metastatic solid tumors remains poor, 
as they are typically incurable.  This phenomenon accentuates 
the need for new therapeutic approaches.4 Immunotherapy, 
commonly defined as treatment of disease by inducing, 
enhancing, or suppressing an immune response, has become 
the mainstay of pharmaceutical innovation.5,6 Immuno-
oncology (I-O) is the area of cancer research that focuses on 
understanding the interaction of the immune system with 
cancer cells and discovers ways to use or enhance the 
patient’s own immune system to stop the growth of cancer 
cells.7,8 The concept of I-O dates back to the 18th century when 
William B. Coley injected streptococcal organisms into a 
patient with inoperable cancer.9,10  Dr. Coley’s injection, which 
became known as Coley’s toxins, resulted in shrinkage of the 
tumor.11  
 
The emergence of I-O agents is changing the landscape of the 
management of metastatic stage IV cancer, offering potential 
for long-term survival and improved quality of life.5,6 The main 
types of immunotherapy presently used to treat cancer 
include monoclonal antibodies, immune checkpoint inhibitors  
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 (ICIs), therapeutic cancer vaccines, and other non-specific 
immunotherapies.12,13 Tumor-specific monoclonal antibodies 
can elicit a direct or indirect immune response that leads to cell 
death. There is a variety of monoclonal antibodies that work via 
different mechanisms of action to cause cell death.12,13 Immune 
checkpoints refer to a group of molecules on the surface of 
both self-cells and cells of the immune system that send a co-
inhibitory stimulus that attenuates an immune response. ICIs 
overcome negative regulatory mechanisms utilized by tumor 
cells to evade the immune system. Therapeutic cancer vaccines 
are designed to stimulate the patient’s own immune system 
against tumor antigens.12,13 Non-specific immunotherapies 
stimulate the immune system in a general way to increase 
activity against cancer cells.12,13 Some examples include man-
made versions of cytokines, a chemical in immune cells, such as 
interleukins and interferons.12,13 Checkpoint inhibitors are the 
most rapidly evolving class of immunotherapy drugs and 
provide the most extensive data for discussion. The cost of I-O 
drugs is remarkably higher compared to standard-of-care, with 
an average price ranging between $120,000 to $150,000 for a 
year of treatment in the U.S.14,15 The high price of novel cancer 
agents is placing increasing pressure on limited healthcare 
budgets. Therefore, the economic impact of the development 
and use of I-O drugs is an important consideration for pricing 
and reimbursement policies. This paper outlines general 
principles of economic evaluations and health-related policies 
for cancer immunotherapy, with a focus on checkpoint 
inhibitors. The objective of this paper is multifold: (i) to identify 
the factors affecting the impact of cancer immunotherapy on 
healthcare cost; (ii) to critically appraise current approaches 
used to assess the value of novel cancer therapies; (iii) to assess 
the methodological challenges associated with the economic 
evaluation of cancer immunotherapy. 
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Health Policy in the Era of Cancer Immunotherapy  
According to an IMS Health's Global Oncology Trend Report, 
worldwide spending on oncology medications has grown to 
$113 billion in 2016, an increase from $91 billion five years 
earlier.16 The U.S represents the largest market for oncology 
drugs accounting for approximately 46% of total spending.16 
Spending has been mostly attributed to the rising cost of 
cancer drugs.3,17 The average per capita price of cancer drugs 
for one year of therapy in the U.S. has increased from $5,000-
$10,000 before the year 2000 to more than $100,000 by 2012.  
However, little correlation between the actual efficacy of the 
new drugs and their prices has been elucidated.18 I-O agents 
are clearly at the forefront of the debate about drug pricing 
since the approval of diverse agents in recent years and with 
more products in clinical development. The price for one 
month of treatment at initial FDA approval was $39,947 for 
ipilimumab (for a Progression Free Survival (PFS) of 2.9 
months), $8,725 for pembrolizumab (for an Overall Response 
Rate (ORR) of 26%), and $12,500 for nivolumab (for a PFS of 
6.9 months). The global immunotherapy drugs market is large 
and is projected to reach $201.52 billion by 2021 from $108.41 
billion in 2016.19 
 
Many countries have adopted a unique mechanism in an 
attempt to control pharmaceutical expenditures, ensure value 
for money and sustainability, and facilitate patient access. This 
mechanism consists of health technology assessment (HTA) 
programs that consider clinical safety and efficacy, price, and 
overall value before a recommendation for reimbursement is 
made for a new cancer drug. These programs are established 
through agencies in countries including Britain (National 
Institute for Health and Care Excellence [NICE]), Australia 
(Pharmaceutical Benefits Advisory Committee [PBAC]), 
Sweden (Swedish Council on Technology Assessment in Health 
Care [SBU]), the Netherlands (Dutch Healthcare Insurance 
Board/College voor Zorgverzekeringen [CVZ]), and Germany 
(Institute for Quality and Efficiency in Health Care [IQWIG]). In 
Canada, oncology drugs are reviewed by a separate entity, the 
pan-Canadian Oncology Drug Review (pCODR). In contrast to 
other developed countries, the U.S does not have a formalized 
HTA system.20,21 
 
The uncertainty that might arise with coverage decision of I-O 
agents could be well illustrated with the case of Sipuleucel-T, 
an autologous cellular immunotherapy for the treatment of 
asymptomatic or minimally symptomatic metastatic castrate-
resistant prostate cancer, which costs approximately $93,000 
for a typical three-course cycle.22 Sipuleucel-T was FDA 
approved in 2010 after a phase 3 trial demonstrated a median 
overall survival (OS) benefit of 4 months compared to the 
control group. After FDA approval, the U.S Centers for 
Medicare & Medicaid Services (CMS) made the unusual move 
to launch a National Coverage Analysis to review the labeled 
use of Sipuleucel-T to determine whether it improved health 
outcomes and if it should still be covered for the Medicare 
population. On March 30, 2011, the CMS announced their final 
national coverage determination for Sipuleucel-T and 
indicated that the drug improved health outcomes for its 
beneficiaries. 23 In the UK, NICE has not recommended 
Sipuleucel-T for treating adults who have asymptomatic or 
minimally symptomatic metastatic non-visceral hormone-
relapsed prostate cancer for which chemotherapy is not yet 
clinically indicated because the available evidence determined 
that the price the National Health Service (NHS) is required to 
pay for the drug is too high for the benefit it may provide to 
patients.24 The NICE evaluation Committee indicated that the 
cost per quality-adjusted life year (QALY) for Sipuleucel-T was 
well above the threshold range usually considered a cost-
effective use of UK NHS resources (i.e., £20,000–£30,000 per 
QALY gained) and that Sipuleucel-T did not meet the criteria 
for end-of-life consideration. The controversy about the 
coverage decision of Sipuleucel-T opens a new avenue for 
Medicare decisions and future coverage. 
 
Although regulations in the U.S. concerning cancer drugs faces 
many challenges, the pricing policy has doubtlessly improved 
over the last two decades. Nevertheless, some important 
factors should be addressed in the future policy agenda.25 The 
American Association of Clinical Oncology (ASCO) has done a 
very good job at highlighting some of these factors in a 2015 
report. Specifically, ASCO has put forth a multiple innovative 
payment and care delivery models recommending that: (a) 
CMS expands its efforts to pilot alternative payment models 
beyond its Oncology Care Model; (b) Congress provides a fair, 
adequate and stable payment environment for oncology 
practice; (c) Private insurers partner with CMS, patients, and 
providers to test promising new payment and care delivery 
models;(d) Oncology professionals engage in 
testing/evaluating new payment and care delivery models. 
 
Economic Value of Immuno-Oncology Therapies 
“Value represents a composite measure of drug utility 
consisting of clinical, economic and quality of life (QOL) related 
attributes.”26  The QALY as part of the incremental cost-
effectiveness ratio (ICER) combines these three attributes into 
a single measure that puts a figure on the benefits of most 
health-care interventions. The QALY is currently 
recommended as reference case by various HTA agencies. The 
cost-per-QALY threshold varies substantially by country 
because not only does gross domestic product (GDP) vary by 
country, but guidelines for conducting pharmacoeconomics 
research also differ depending on the country.27 In the UK, 
NICE uses a threshold in the range of £20,000 to £30,000, and 
above a most plausible ICER of £30,000 per QALY gained.28 In 
Australia, there is no specific threshold for approval; however, 
between 1994 and 2003, the highest cost per QALY at which a 
drug was recommended for listing was Australian $52,400.29 
Above this value, 9 of 11 applications were rejected or 
withdrawn by the manufacturer and two were given only 
conditional approval (subject to price reductions).29 The 
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Netherlands has no formal threshold, yet a cutoff value at 
€20,000 per QALY is often cited in various reports.30,31 In the 
literature, as well as many other jurisdictions, the commonly 
used threshold is $50,000 cost per QALY gained.31,32  
 
The World Health Organization (WHO) considers a drug to be 
cost-effective if its threshold value is within one to three times 
the local GDP per capita per QALY gained.33 However, the 
rationality of this suggested threshold draws controversy.31,34 
For illustration purposes, using a high-income country like the 
U.S. (i.e., per capita GDP = $54,629.50), the three-time 
threshold for cost-effectiveness would be roughly $163,888.50 
per QALY gained. For an upper-middle-income country such as 
Mexico (per capita GDP = $10,230.20), the cost per QALY 
gained threshold would be U.S $30,690.60 (The World Bank, 
2015). For a lower-middle-income country such as Indonesia 
(per capita GDP = $3,491.90), the cost per QALY gained 
threshold would be $10,475.70. In contrast, the threshold for 
economic value for a low-income country, such as Liberia (per 
capita GDP = $461.00) would be $1,383 per QALY gained (The 
World Bank, 2015). Based on this logic, the price of the same 
drug would considerably vary from one country to another. 
While the cost per QALY of many new cancer drugs is 
contentious to estimate, they often exceed the threshold of 
$100,000 per QALY gained.  
 
Critics have expressed concerns over the ethics and equity 
associated with valuing health gains in terms of QALYs and the 
appropriateness of its use in health care decision-making.35,36 
In fact, QALY may discriminate between individuals on age 
grounds since younger individuals are more likely to be 
healthier while the elderly are more prone to sickness.37  In 
recent years, many countries have taken a stance on QALY 
thresholds. In the UK, NICE has proposed to no longer use the 
cost-per-QALY information to make recommendations, but 
rather rely on cost-effectiveness assessments to provide input 
into price negotiations for new technologies.38 In Germany, 
the IQWIG implemented a new system for estimating the 
value of medical technologies but rejected the cost-per-QALY 
model on ethical and methodological grounds.39 In cases of 
uncertainty about the relative effectiveness, payers are 
turning to novel concepts such as value-based pricing (VBP). 
 
Value-based pricing  
Value-based health care has moved to the forefront of the 
health policy agenda, as public payers search for an approach 
to improve outcomes while containing cost.40  However, the 
U.S. has yet to learn from the experiences of other 
industrialized countries by including the concepts of cost-
effectiveness (CEA) and VBP as part of reimbursement 
decision-making, which may lead to improved outcomes for 
patients. Value-based pricing consists of negotiating prices for 
new pharmaceuticals based on the value the new drug offers 
society, as assessed through HTA.41,42 In the UK, there is 
already a version of VBP in place for new cancer medicines, 
which defines their maximum acceptable NHS prices.43,44 In 
the U.S., the government does not provide adequate leverage 
in negotiating drug prices. Medicare, the government’s largest 
health plan does not directly negotiate with drug 
manufacturers over prices for prescription drugs covered 
under the Part B benefit or the oral anticancer drugs covered 
under Medicare’s pharmacy “Part D” benefit.45,46 
Consequently, as effective and more expensive ICIs are 
introduced to the U.S. market, Medicare is left with no other 
alternative than to pay for these costly drugs. Countries whose 
law favors the active role of government in pharmaceutical 
price negotiations have resorted to the VBP concept to reduce 
pharmaceutical expenditures.47  
 
Several value frameworks have been developed to assess the 
value of cancer drugs, including those by the Institute for 
Clinical and Economic Review (ICER), the American Society of 
Clinical Oncology (ASCO), the National Comprehensive Cancer 
Network (NCCN), and the Memorial Sloan Kettering (MSK) 
cancer center DrugAbacus. The ICER Value Assessment 
Framework offers a source of information that can act as the 
backbone of discussions between insurers, providers, patients, 
and policymakers regarding matters related to pricing, 
payment, and the use of new drugs. ICER’s Value Assessment 
Framework separates value into two components: “care 
value” and “provisional health system value.”48,49  Care value 
assessment takes into account comparative clinical 
effectiveness, incremental costs per outcomes achieved other 
benefits or disadvantages, and contextual considerations such 
as ethical and legal concerns that shape the relative priority of 
the intervention. Provisional health system value is assessed 
based on whether medication could treat a population with 
reasonable long-term value and considers the short-term 
budget impact that would not lead to excessive health care 
expenditure. 
 
The ASCO value framework developed guidelines to help 
clinicians, patients, and families through effective shared 
decision-making to best evaluate treatment options for 
cancer.50 This framework seeks to ensure that intervention 
costs result directly in beneficial impacts for patients.  
 
The NCCN Evidence Blocks have been devised to ease 
discussions between physicians and patients for elements of 
informed decision-making.51 It is presented as a visual 
representation of five value measures that provide important 
information about specific recommendations found in the 
NCCN Guidelines including efficacy, safety, quality of evidence, 
consistency of evidence, and affordability.51  
 
MSK’s DrugAbacus is a publicly available online tool that 
allows users to easily calculate the price for a cancer drug 
based on their chosen settings for its value.52 DrugAbacus 
measures value according to six components: the value of a 
life year, toxicity, treatment novelty, research and 
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development costs, the rarity of the disease it targets, and the 
population health burden the targeted disease causes. 
 
The need to define value in cancer therapy stems from the 
continuous growth of both healthcare demand and 
consumption. The implementation of a VBP scheme in the U.S 
offers an opportunity to provide patients timely access to 
drugs, and control drug prices. However, before such a 
scheme can be implemented, some policies may need to be 
revised to allow public programs to take advantage of diverse 
systematic evaluation methods to assess the value of new 
drugs and to negotiate directly with pharmaceutical 
manufacturers on price based on their assessment findings. It 
is also worth underlining that even though the introduction of 
VBP would safeguard access to effective and innovative IO 
agents by setting a price that reflects the utility created, it can 
deter innovation. The VBP scheme is also a single component 
of many moving parts and this system alone will not address 
all the concerns over the costs for cancer medications. 
 
Reimbursement and Patient Access  
In an era of unsustainable pricing and the difficulties to define 
the value of I-O drugs, reimbursement challenges may arise. 
The clinical and/or economic value attributable to I-O drugs is 
not well established at the moment. There is no evidence to 
support whether existing HTA framework and reimbursement 
processes are appropriate for the new generation of I-O drugs. 
Therefore, there may be consequences in making 
unsustainable reimbursement decisions. Instead of the current 
fee-for-service system,53 an improved reimbursement system 
adapted to novel cancer therapies is warranted. Ideally, under 
such reimbursement, the cost of I-O agents would be 
negotiated based on the value that they provide to patients. 
Patient access to costly new cancer drugs is of great interest 
and concern to all stakeholders including patients, physicians, 
payers, manufacturers, and policymakers, who are seeking to 
limit coverage to subpopulation most likely to benefit from 
these drugs.54  
 
The U.S has a comprehensive mechanism whereby important 
new drugs become available to American consumers faster 
than the existing standard and priority review programs  
for certain conditions including cancer.55 The national 
“Moonshot” initiative to cure cancer initiative is expected to 
streamline bureaucracy so patients can have easy access to 
new drugs such as promising new drug combinations.56 Yet, 
there are structural barriers that may prevent patient access 
to I-O drugs.57 When considering strategies to improve access, 
one must consider the effectiveness of clinical trials in 
providing sound evidence translatable to broad patient 
populations. This places an emphasis on trial designs that 
value inclusivity and use appropriate surrogates as well as 
predictive markers. Trials are also needed to compare the 
efficacies of competitor products and utilize “adaptive 
licensing” plans. 
Once therapies are introduced into practice, evidence should 
subsequently be collected, evaluated, and made available to 
constituencies responsible for delivery and reimbursement. 
Policies should promote greater understanding of the 
potential benefits of I-O drugs and illustrate how they differ 
from other cancer therapies. Outcomes-based agreements 
between pharmaceutical and insurance companies such as 
value-based payments and risk-sharing agreements should be 
incentivized. These outcome-based agreements would seek to 
address what really matters to patients, which is long-term 
quality survival and safety of therapies with the goal of 
ultimately improving patient access. Medicare should be given 
the mandate to negotiate prices for high-cost drugs with 
pharmaceutical manufacturers, which would likely lead to 
significant overall cost savings. Furthermore, competition 
should be encouraged to leverage price negotiation, and 
funding for innovative, socially responsible research on I-O 
agents should be increased. 
 
Considerations for Economic Evaluation 
As new health care strategies compete with existing ones for 
limited resources in environments with limited resources, all 
levels of the health care system are relying on economic 
evaluations to achieve maximum value for money and to  
help inform decision making.58,59 In many countries, 
Pharmacoeconomic Evaluations (PEs) plays an increasingly 
important role in informing clinical development and market 
access decisions of new innovative medicines.60,61 Since there 
is a lack of information on whether new considerations are to 
be included in the PE of I-O drugs, a search of the literature 
was performed to identify all peer-reviewed published articles 
on PEs of marketed ICI therapies (ipilimumab, pembrolizumab, 
and nivolumab) and comment on the modes of evaluation. 
The literature search identified only one cost-effectiveness 
study of ipilimumab.62 There are several factors which may 
explain the scarcity of PE literature on ICI. First, International 
health technology assessment HTA agencies often do not 
publish in the peer-reviewed literature or publish sometime 
after the evaluation is complete. Economic evaluations of ICIs 
will therefore likely be in the grey literature. Second, ICIs may 
have not been studied extensively, partly due to their novelty. 
 
Due to recent emergence, there are several challenges 
looming with the PE of ICIs, mainly related to methodological 
issues. The mechanism of action of ICIs tends to result in 
delayed clinical effect.63 The clinical experience of ipilimumab 
has shown that complete response (CR), partial response (PR), 
or stable disease status can still be achieved after an initial 
increase in the overall tumor burden.64,65 The unique 
characteristics of ICIs also produce long-term survival, 
resulting in a delay in separation of Kaplan-Meier (KM) survival 
curves between the control and treatment arms of clinical 
trials.66-68 For instance, KM curves of OS in patients treated 
with ipilimumab show that survival consistently reaches a 
plateau at around 2 to 3 years,66,69,70 as demonstrated in both 
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randomized phase 3 trials of ipilimumab in metastatic 
melanoma. Beyond this time point, the long “tail” of the 
survival curve reflects the emergence of long-term survivors. 
Data models for delayed effects of treatment on time-to-event 
endpoints such as survival violate the proportional hazards 
assumption.71 The proportional hazards assumption stipulates 
that the survival curves for two strata must have hazard 
functions that are proportional over time (i.e. constant relative 
hazard). In other terms, the ratio of hazards is constant and 
does not depend on time. The unique characteristics of the 
long-term survival and delayed clinical effect in melanoma 
constitute a challenge to PE. The point is that the KM curve 
assumption of proportional hazards (which is violated) and 
long-term survivors do not apply to standard analytical 
approaches for OS extrapolation beyond the study follow-up 
time of the clinical trial. Nonetheless, OS will vary depending 
on the clinical indication that is being treated and the 'delayed 
effect' observed for melanoma may not be seen with other 
cancers. Similarly, not all survival curves for all clinical 
indications that receive ICIs will violate the proportional 
hazards assumption. Therefore, economic evaluation of ICIs 
will require caution and in many cases will require the 
utilization of innovative analytical tools. Several methods have 
been proposed to overcome some of these challenges. 
Regarding the delayed clinical effect, in their CEA study of 
ipilimumab, Barzey et al. indicated that the best fitting 
parametric curve (lognormal) did not adequately represent 
the survival of ipilimumab patients.62 Therefore, their analysis 
used an alternative, non-parametric method, which assumed 
that patients died at a constant rate. Chen proposed the 
weighted log-rank test as an exploratory analysis to account 
for the delayed separation of KM curves.72 Using the 
experience of ipilimumab, Annemans and colleagues explored 
two approaches.73 The first method involved a “selected 
hazard rate” approach which reflected clinical prognosis. The 
second method was a “broken curve” approach, which found 
the best mathematical fit of standard survival models within 
subsets of available data, combined with the use of external 
epidemiology data. Their investigation then used the Akaike’s 
Information Criterion (AIC),74 a measure of the relative quality 
of statistical models, to determine the best-fit curve.  
 
Due to relative novelty, RCT evidence for ICIs should be 
substantiated with observational studies. Ongoing 
developments in data and analytical techniques, such as data 
linkage and propensity score methods, and instrumental 
variables offer a promising future for observational 
studies.75,76 Economic evaluation requires an appropriate time 
horizon to fully capture the costs and benefits between the 
alternative being compared during and beyond the trial. 
However, RCTs are often characterized by their short time 
horizon. The extent to which the findings of a clinical trial can 
be reliably extrapolated from the subjects who participated in 
the trial to a broader patient population and a range of clinical 
settings is questionable. Well-designed observational studies 
can be a reliable tool for addressing the issue of time horizon 
and generalizing the results of RCTs. In observational studies, 
individuals are followed for an extended period and are more 
similar to real-life patients. One of the drawbacks of 
observational studies is their limited applicability for decision-
making purposes because the data are usually available after 
regulatory approval and reimbursement.  
 
High-quality economic evaluation plays a major role in 
decision making. Understanding and quantifying the 
uncertainty in an economic evaluation model is paramount to 
enable decision-makers to correctly interpret the results for 
specific outcomes, determine whether those results are robust 
and acceptable to approve an IO agent for use. Quantification 
of decision uncertainty in economic evaluation may be 
improved through the application of value of information 
methods, and conducting of probabilistic sensitivity analysis. 
 
Conclusion 
With health care costs rising, payers are seeking strategies to 
contain spending in all areas including prescription drugs. I-O 
drugs have the potential to revolutionize pharmacotherapy of 
tumor metastasis and cancer. However, due to their high 
costs, I-O may also revolutionize spending on prescription 
drugs. Because of this confluence, stakeholders including 
patients, physicians, policy-makers, and pharmaceutical 
companies are grappling with new approaches to price setting 
and drug value assessment. I-O, like most novel cancer 
therapies, is complex. Thus there is a need to develop 
appropriate and robust economic evaluation methods to 
provide a basis for decision-making. Appropriate HTA of I-O 
drugs is critical to demonstrate their benefit, quantify their 
potential value, and guide reimbursement decisions. 
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